I Notice The Negative Aspects Of My Job, Articles A

The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. AbbVie passed that onto its 2022 guidance. GSK Stock Forecast 2023 - 2025 - 2030 | StockForecast.com All rights reserved. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Get daily stock ideas from top-performing Wall Street analysts. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. All Rights Reserved. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. Receive ABBV Stock News and Ratings via Email. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. AbbVie could be the biggest global Pharma by revenue generation in 2028. Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Get short term trading ideas from the MarketBeat Idea Engine. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. And never invest or trade money you cannot afford to lose. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. View AbbVie's Short Interest. We expect that to happen in 2027 with continued significant growth anticipated in the following years. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Please disable your ad-blocker and refresh. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . Enjoy your holiday weekend and catch up on our most read stories this week. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. All rights reserved. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions). AbbVie income statement forecast (My table and assumptions). View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. The Abbvie stock forecast for 2025 had the price at $259.018. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. Abbvie (ABBV) stock price prediction is 262.23586323343 USD. The Abbvie The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. My No. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook Receive regular, detailed analysis focused on biotech and healthcare stocks. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. Aurora Cannabis Stock Forecast for 2023 - 2025 - 2030 Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Abbvies first quarter 2022 financial results for the quarter ended 31 March revealed that diluted earnings per share (EPS) increased to $2.51 on a generally accepted accounting principles (GAAP) basis, up from $1.99 a year earlier. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. What other stocks do shareholders of AbbVie own? Abbvie Stock Forecast 2023, 2024, 2025, 2030 - Stock in US Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you have an ad-blocker enabled you may be blocked from proceeding. ABBV currently yields 4.1% and has raised its dividend every year since 2013. About the AbbVie, Inc. stock forecast. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. Price target. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Build a CFD portfolio with your favourite companies. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. The dividend payout ratio is 89.56%. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. PEG Ratios above 1 indicate that a company could be overvalued. ABBV - AbbVie Stock Prediction 2025 - 2030 Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. ABBV has several positive factors pushing its price performance. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. (AbbVie JPM Healthcare conference presentation). One share of ABBV stock can currently be purchased for approximately $156.06. The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. I wrote this article myself, and it expresses my own opinions. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. Rinvoq's progress has been a little more circumspect, but almost as impressive. Only you can design whether Abbvie stock is the right investment for you. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. That reflects uncertainty about what the future holds for AbbVie. One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. Johnson & Johnson Stock Forecast 2023 - 2025 - 2030 Discovery Company. AbbVie Stock: A Blue Chip You Cannot Afford To Miss, Yield 4.1% Abbvie Stock Forecast | Is Abbvie a Good Stock to Buy? - Capital Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". Please log in to your account or sign up in order to add this asset to your watchlist. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. The analysts 12-month consensus ABBV stock price target was $159.75. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. Abbvie Stock Forecast: up to 179.050 USD! - Walletinvestor.com ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. The company issued revenue guidance of -. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. You should consider whether you understand how CFDs work and can afford the risks. As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Research Reports & Trade Ideas - Yahoo Finance Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. AbbVie projected sales - immunology (my forecasts and assumptions). Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. (my tables and forecasting). Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. (my table and forecasts). AbbVie Inc. (ABBV) Stock Forecast & Price Targets - Stock Analysis Forecasts shouldnt be used as a substitute for your own research. Export data to Excel for your own analysis. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Finally, AbbVie was able to raise its financial . When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . Morningstar: 2019 Morningstar, Inc. All Rights Reserved. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. Disclaimer. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. The stocks growth marks a significant outperformance over the broader markets. 1 dividend stock for a LIFETIME of income. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. Always conduct your own due diligence before investing. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Since then, however, the stock price has fallen 18% to its current price of $142.6. To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. AbbVie: Modelling The Post Humira Bull Case To 2030 (ABBV) AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. ABBV : ABBVIE INC stock forecast 2022 - 2025 - 2030 - AI Pickup The ex-dividend date of this dividend is Thursday, April 13th. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. What is the dividend yield for AbbVie? Move your mouse over a quarter or year to see how estimates have changed over time. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. Teliso V is an antibody drug conjugate and a c-Met inhibitor. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. Multidrug Resistant Bacteria Treatment Market - MarketWatch The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. . 164.71 0.00 0.00%. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. I am not receiving compensation for it (other than from Seeking Alpha). Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. AbbVie has been increasing its dividend for 51 years. A Warner Bros. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January.